Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Julphar
Dow
Cipla
Queensland Health
Harvard Business School
Argus Health
McKinsey

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,592,434

« Back to Dashboard

Which drugs does patent 8,592,434 protect, and when does it expire?

Patent 8,592,434 protects SITAVIG and is included in one NDA.

This patent has six patent family members in five countries.
Summary for Patent: 8,592,434
Title:Mucoadhesive buccal tablets for the treatment of orofacial herpes
Abstract: The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.
Inventor(s): Attali; Pierre (Vincennes, FR), Costantini; Dominique (Paris, FR), Lemarchand; Caroline (Paris, FR)
Assignee: BioAlliance Pharma SA (Paris, FR)
Application Number:12/634,225
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,592,434

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Epi Hlth SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF HERPES LABIALIS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,592,434

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2782779 ➤ Try a Free Trial
China 102652016 ➤ Try a Free Trial
European Patent Office 2335690 ➤ Try a Free Trial
European Patent Office 2509586 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
QuintilesIMS
Deloitte
Express Scripts
Daiichi Sankyo
Accenture
Harvard Business School
Colorcon
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.